Plain aspirin — Competitive Intelligence Brief

Plain aspirin (Plain aspirin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent. Area: Cardiovascular; Pain management; Inflammation.

marketed Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) Cardiovascular; Pain management; Inflammation Small molecule

Target snapshot

Plain aspirin (Plain aspirin) — Royal College of Surgeons, Ireland. Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and blood clotting.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Plain aspirin TARGET	Plain aspirin	Royal College of Surgeons, Ireland	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Topical NSAID	Topical NSAID	University of Nottingham	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and/or COX-2)
lysine acetylsalicylate	lysine acetylsalicylate	Azienda Ospedaliera San Giovanni Battista	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
High Dose Ibuprofen	High Dose Ibuprofen	Ottawa Hospital Research Institute	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Loxoprofen sodium hydrogel patch	Loxoprofen sodium hydrogel patch	Sun Yat-sen University	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Acetylsalicylic Acid (ASA)	Acetylsalicylic Acid (ASA)	Sunnybrook Health Sciences Centre	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Aspirin monotherapy	Aspirin monotherapy	Harbin Medical University	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent class)

1. Assistance Publique - Hôpitaux de Paris · 3 drugs in this class
2. Basque Health Service · 2 drugs in this class
3. PLx Pharma · 2 drugs in this class
4. Biogen · 1 drug in this class
5. Eli Lilly and Company · 1 drug in this class
6. Harbin Medical University · 1 drug in this class
7. Janssen Scientific Affairs, LLC · 1 drug in this class
8. Azienda Ospedaliera San Giovanni Battista · 1 drug in this class
9. Royal College of Surgeons, Ireland · 1 drug in this class
10. Shiraz University of Medical Sciences · 1 drug in this class